Inhibition and degradation of NRAS with a pan-NRAS monobody

Oncogene. 2024 Nov;43(48):3489-3497. doi: 10.1038/s41388-024-03186-y.

Michael Whaby ¹ ², Gayatri Ketavarapu ³, Akiko Koide ³ ⁴, Megan Mazzei ¹ ², Mubashir Mintoo ¹ ² ⁵, Eliezra Glasser ³, Unnatiben Patel ³, Cecile Nasarre ¹ ² ⁵, Matthew J Sale ⁶ ⁷, Frank McCormick ⁶ ⁷, Shohei Koide ⁸ ⁹, John P O'Bryan ¹⁰ ¹¹ ¹² ¹³

Affiliations

1 Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA.
2 Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
3 Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.
4 Department of Medicine, New York University School of Medicine, New York, NY, USA.
5 Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.
6 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
7 Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
8 Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA. [email protected].
9 Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA. [email protected].
10 Department of Cell and Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, USA. [email protected].
11 Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA. [email protected].
12 Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA. [email protected].
13 Ralph H. Johnson VA Medical Center, Charleston, SC, USA. [email protected].

PMID: 39379700 DOI: 10.1038/s41388-024-03186-y

Abstract

The Ras family GTPases are the most frequently mutated oncogene family in human cancers. Activating mutations in either of the three Ras isoforms (HRAS, KRAS, or NRAS) are found in nearly 20% of all human tumors with NRAS mutated in ~25% of melanomas. Despite remarkable advancements in therapies targeted against mutant KRAS, NRAS-specific pharmacologics are lacking. Thus, development of inhibitors of NRAS would address a critical unmet need to treating primary tumors harboring NRAS mutations as well as BRAF-mutant melanomas, which frequently develop resistance to clinically approved BRAF inhibitors through NRAS mutation. Building upon our previous studies with the monobody NS1 that recognizes HRAS and KRAS but not NRAS, here we report the development of a monobody that specifically binds to both GDP and GTP-bound states of NRAS and inhibits NRAS-mediated signaling in a mutation-agnostic manner. Further, this monobody can be formatted into a genetically encoded NRAS-specific degrader. Our study highlights the feasibility of developing NRAS selective inhibitors for therapeutic efforts.

Name
Email *

	Sorry, but the email address you supplied was invalid.